Silver Nanoparticle Synthesis Using Ascorbic Acid Derivatives
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing silver nanoparticles often result in aggregation, require toxic stabilizing agents, and produce harmful by-products, limiting their application and efficiency in fields like wound healing and antimicrobial treatments.
Innovation Solution
A method involving specific reducing agents, such as ascorbic acid derivatives, is used to control the redox potential and size of silver nanoparticles, eliminating free silver ions and using polysaccharides as stabilizing agents to prevent aggregation and enable safer, more effective production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If chemical reduction methods are used to produce silver nanoparticles, then silver nanoparticles can be synthesized, but aggregation occurs and toxic stabilizing agents are required
Solution Approach 1:
The patent uses ascorbic acid and its derivatives as intermediary reducing agents that enable controlled reduction of silver salts to nanoparticles without requiring toxic stabilizing agents. These intermediaries provide both reduction functionality and stabilization through their molecular structure, eliminating the need for separate toxic stabilizers while preventing aggregation.
Solution Approach 2:
The patent controls nanoparticle synthesis by adjusting parameters including the specific ascorbic acid derivative used, molar ratios of reactants, temperature (maintaining below 50°C for certain formulations), and pH conditions. These parameter changes enable precise control over nanoparticle size, shape, and stability without aggregation or toxic additives.
2Reliability
If ionic silver compounds are used for antimicrobial treatment, then strong antimicrobial properties are achieved, but side effects occur
Solution Approach 1:
The patent employs silver nanoparticles as a disposable, controlled-release antimicrobial agent that delivers therapeutic effect locally at the application site without systemic circulation of ionic silver. The nanoparticles provide sustained antimicrobial action through controlled ion release, achieving reliable efficacy while minimizing systemic side effects through localized, controlled delivery.
3Object-affected harmful factors
If modern antibiotics are used instead of silver compounds, then side effects are reduced, but antimicrobial properties are weaker
Solution Approach 1:
The patent creates composite structures where silver nanoparticles are incorporated into various delivery systems including hydrogels, microparticles, and topical formulations. These composite materials combine the strong antimicrobial properties of silver with biocompatible carriers, achieving both high efficacy and low toxicity through the synergistic combination of antimicrobial agent and safe delivery vehicle.
4Stability of the object's composition
If stabilizing agents are added to prevent aggregation, then nanoparticle stability is improved, but toxic by-products are generated
Solution Approach 1:
The patent employs ascorbic acid derivatives that provide self-stabilization through their molecular structure. The reducing agent molecules remain associated with the nanoparticle surface after reduction, providing steric and electrostatic stabilization without requiring additional toxic stabilizing agents. This self-service approach eliminates the need for separate stabilizers and their associated toxic by-products.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach yields silver nanoparticles with controlled size distribution, reduced toxicity, and enhanced stability, suitable for topical applications, wound treatment, and antimicrobial uses without harmful by-products, improving their efficacy and safety.
Implementation Method 1
The chemical reduction methods are based on reduction of silver salt with a number of reducing agents including sodium citrate, sodium borohydride, hydroxylamine hydrochloride, hydrazine, and ethylenediaminetetraacetic acid (EDTA), ascorbic acid, polyol, etc.
Implementation Method 2
A stabilizing agent needs to be added to the reaction mixture to prevent the aggregation of the silver nanoparticles formed unless the reducing agent itself is a stabilizing agent (such as citrate).
Implementation Method 3
A method involving specific reducing agents, such as ascorbic acid derivatives, is used to control the redox potential and size of silver nanoparticles, eliminating free silver ions
Implementation Method 4
using polysaccharides as stabilizing agents to prevent aggregation and enable safer, more effective production
Data Source
AI summary
Disclosed herein is a micro particle with a diameter of 10-100 microns, wherein the micro particle is coated with silver nanoparticles; and wherein the nanoparticles are coated with a polysaccharide; and wherein the polysaccharide coating is digestible by bacteria. Also, disclosed is a method of making silver nanoparticles using an ascorbic acid derivative or an alpha-hydroxyl carboxylic acid derivative as a reducing agent. The silver nanoparticles may be coated onto micro particles, embedded in hydrogel particles or coated with polysaccharide. The silver nanoparticles may be used in a wound dressing, a bandage, a fungal treatment product, a deodorant, a floss product, a toothpick, a dietary supplement, dental X-ray, a mouthwash, a toothpaste, acne or wound treatment product, skin scrub, and skin defoliate agent.